Advertisement
Advertisement

RZLT

RZLT logo

Rezolute, Inc. Common Stock (NV)

3.25
USD
Sponsored
0.00
-0.03%
Mar 27, 09:33 UTC -4
Open

RZLT Earnings Reports

Positive Surprise Ratio

RZLT beat 17 of 27 last estimates.

63%

Next Report

Date of Next Report
May 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.17
Implied change from Q2 26 (Revenue/ EPS)
--
/
-22.73%
Implied change from Q3 25 (Revenue/ EPS)
--
/
-37.04%

Rezolute, Inc. Common Stock (NV) earnings per share and revenue

On Feb 12, 2026, RZLT reported earnings of -0.22 USD per share (EPS) for Q2 26, missing the estimate of -0.19 USD, resulting in a -15.36% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.79% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of -0.17 USD, with revenue projected to reach -- USD, implying an decrease of -22.73% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
logo
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
logo
Acumen Pharmaceuticals, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.46
Actual
-$0.41
Surprise
+11.29%
logo
Spero Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.20
Actual
$0.53
Surprise
+359.80%
logo
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.07
Surprise
-2.94%
logo
Alpha Cognition Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.30
Surprise
-8.93%
logo
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
logo
Cognition Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.02
Surprise
+76.47%
logo
Quantum Biopharma Ltd. Class B Subordinate Voting Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-
Actual
-$0.71
Surprise
-
logo
CollPlant Biotechnologies Ltd Ordinary Shares
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.67
Surprise
-245.72%
FAQ
For Q2 2026, Rezolute, Inc. Common Stock (NV) reported EPS of -$0.22, missing estimates by -15.36%, and revenue of $0.00, 0% as expectations.
The stock price moved up 5.79%, changed from $3.63 before the earnings release to $3.84 the day after.
The next earning report is scheduled for May 11, 2026.
Based on 12 analysts, Rezolute, Inc. Common Stock (NV) is expected to report EPS of -$0.17 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement